| Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease A Beilina, IN Rudenko, A Kaganovich, L Civiero, H Chau, SK Kalia, ... Proceedings of the National Academy of Sciences 111 (7), 2626-2631, 2014 | 382 | 2014 |
| The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation E Greggio, I Zambrano, A Kaganovich, A Beilina, JM Taymans, V Daniëls, ... Journal of Biological Chemistry 283 (24), 16906-16914, 2008 | 375 | 2008 |
| Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis L Parisiadou, C Xie, HJ Cho, X Lin, XL Gu, CX Long, E Lobbestael, ... Journal of Neuroscience 29 (44), 13971-13980, 2009 | 370 | 2009 |
| Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain JM Taymans, LH Vandenberghe, CVD Haute, I Thiry, CM Deroose, ... Human gene therapy 18 (3), 195-206, 2007 | 350 | 2007 |
| MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein HJ Cho, G Liu, SM Jin, L Parisiadou, C Xie, J Yu, L Sun, B Ma, J Ding, ... Human molecular genetics 22 (3), 608-620, 2013 | 296 | 2013 |
| Distribution of PINK1 and LRRK2 in rat and mouse brain JM Taymans, C Van den Haute, V Baekelandt Journal of neurochemistry 98 (3), 951-961, 2006 | 212 | 2006 |
| Automated quantitative gait analysis in animal models of movement disorders C Vandeputte, JM Taymans, C Casteels, F Coun, Y Ni, K Van Laere, ... BMC neuroscience 11, 1-11, 2010 | 200 | 2010 |
| The Parkinson’s disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites E Greggio, JM Taymans, EY Zhen, J Ryder, R Vancraenenbroeck, ... Biochemical and biophysical research communications 389 (3), 449-454, 2009 | 191 | 2009 |
| A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation BMH Law, VA Spain, VHL Leinster, R Chia, A Beilina, HJ Cho, ... Journal of Biological Chemistry 289 (2), 895-908, 2014 | 170 | 2014 |
| Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant V Daniëls, R Vancraenenbroeck, BMH Law, E Greggio, E Lobbestael, ... Journal of neurochemistry 116 (2), 304-315, 2011 | 161 | 2011 |
| Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions JM Taymans, JE Leysen, X Langlois Journal of neurochemistry 84 (5), 1118-1127, 2003 | 136 | 2003 |
| Inhibition of FK506 binding proteins reduces α-synuclein aggregation and Parkinson's disease-like pathology M Gerard, A Deleersnijder, V Daniëls, S Schreurs, S Munck, V Reumers, ... Journal of Neuroscience 30 (7), 2454-2463, 2010 | 124 | 2010 |
| Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers L Civiero, R Vancraenenbroeck, E Belluzzi, A Beilina, E Lobbestael, ... Public Library of Science 7 (8), e43472, 2012 | 117 | 2012 |
| LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding JM Taymans, R Vancraenenbroeck, P Ollikainen, A Beilina, E Lobbestael, ... PloS one 6 (8), e23207, 2011 | 116 | 2011 |
| The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation A Kumar, E Greggio, A Beilina, A Kaganovich, D Chan, JM Taymans, ... PloS one 5 (1), e8730, 2010 | 111 | 2010 |
| Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle E Lobbestael, J Zhao, IN Rudenko, A Beylina, F Gao, J Wetter, M Beullens, ... Biochemical Journal 456 (1), 119-128, 2013 | 110 | 2013 |
| Resistance of HIV-1 reverse transcriptase against [2', 5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5 “-(4”-amino-1 “, 2”-oxathiole-2 “, 2”-dioxide)](TSAO) derivatives is … H Jonckheere, JM Taymans, J Balzarini, S Velazquez, MJ Camarasa, ... Journal of Biological Chemistry 269 (41), 25255-25258, 1994 | 100 | 1994 |
| Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation J Madero-Pérez, E Fdez, B Fernández, AJ Lara Ordóñez, ... Molecular neurodegeneration 13, 1-22, 2018 | 89 | 2018 |
| LRRK2 kinase inhibition as a therapeutic strategy for Parkinson’s disease, where do we stand? JM Taymans, E Greggio Current neuropharmacology 14 (3), 214-225, 2016 | 88 | 2016 |
| Differential protein–protein interactions of LRRK 1 and LRRK 2 indicate roles in distinct cellular signaling pathways L Reyniers, MG Del Giudice, L Civiero, E Belluzzi, E Lobbestael, A Beilina, ... Journal of neurochemistry 131 (2), 239-250, 2014 | 88 | 2014 |
Huaibin CaiSenior Investigator, National Institute on Aging, National Institutes of Health在 mail.nih.gov 的电子邮件经过验证
